Arcutis Biotherapeutics
ARQT
ARQT
239 hedge funds and large institutions have $1.95B invested in Arcutis Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 65 increasing their positions, 81 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
4.7% less ownership
Funds ownership: 110.08% → 105.38% (-4.7%)
20% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 81
Holders
239
Holding in Top 10
6
Calls
$13.1M
Puts
$4.26M
Top Buyers
| 1 | +$22.9M | |
| 2 | +$6.41M | |
| 3 | +$5.9M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.07M |
| 5 |
RA
Royce & Associates
New York
|
+$4.19M |
Top Sellers
| 1 | -$28.7M | |
| 2 | -$15.3M | |
| 3 | -$14.4M | |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$10.5M |
| 5 |
JPMorgan Chase & Co
New York
|
-$9.35M |
